Anika Therapeutics (ANIK) SVP RSUs vest; 639 shares withheld for taxes

Rhea-AI Filing Summary

Anika Therapeutics, Inc. SVP, CAO & Treasurer Ian McLeod completed the final vesting of a prior RSU grant and related tax withholding. On March 9, 2026, 2,197 restricted stock units converted into 2,197 shares of common stock, representing the third and final installment of a 6,590‑RSU award granted on March 9, 2023. To cover tax obligations on this vesting, 639 shares were retained by the company at a price of $14.96 per share, leaving a net 1,558 shares from this tranche. After these transactions, McLeod directly holds 18,744 shares of Anika Therapeutics common stock.

Insider Trade Summary

2,197 shares exercised/converted

Mixed 3 txns

Insider McLeod Ian

Role SVP, CAO & Treasurer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	2,197	$0.00	--
Exercise	Common Stock	2,197	$0.00	--
Tax Withholding	Common Stock	639	$14.96	$10K

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 19,383 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 528 shares purchased on May 14, 2025 and 616 shares purchased on November 14, 2025. Reflects an aggregate of 639 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026. On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLeod Ian

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CAO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		M		2,197	A	(1)	19,383(2)	D
Common Stock	03/09/2026		F		639(3)	D	$14.96	18,744	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/09/2026		M			2,197	(4)	(4)	Common Stock	2,197	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 528 shares purchased on May 14, 2025 and 616 shares purchased on November 14, 2025.

3. Reflects an aggregate of 639 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

4. On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

	/s/ Ian McLeod	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Anika Therapeutics (ANIK) SVP Ian McLeod report?

Ian McLeod reported vesting of restricted stock units and related tax withholding. On March 9, 2026, 2,197 RSUs converted into common shares, and 639 of those shares were withheld by the company to satisfy tax obligations tied to the vesting event.

How many Anika Therapeutics (ANIK) shares did Ian McLeod acquire and retain from the RSU vesting?

He acquired 2,197 shares of common stock through RSU conversion. Of these, 639 shares were withheld for taxes, leaving a net 1,558 shares from this vesting. These shares are part of his updated direct ownership position after the transaction.

What is Ian McLeod’s Anika Therapeutics (ANIK) shareholding after this Form 4 filing?

Following the March 9, 2026 transactions, Ian McLeod directly holds 18,744 shares of Anika Therapeutics common stock. This figure reflects the RSU conversion and the 639 shares retained by the issuer to cover associated tax withholding obligations on the vested RSUs.

What RSU grant was involved in Ian McLeod’s Anika Therapeutics (ANIK) Form 4 filing?

The filing relates to a 6,590‑unit RSU grant awarded on March 9, 2023. These RSUs vested in three equal annual installments beginning March 9, 2024, and the March 9, 2026 transaction represents the third and final vesting installment of that award.

Was any part of Ian McLeod’s Anika Therapeutics (ANIK) transaction an open-market sale?

No open-market sale was reported. The disposition of 639 shares was classified as a tax-withholding transaction, where the issuer retained shares at $14.96 per share to satisfy tax liabilities arising from the RSU vesting event on March 9, 2026.

How were the tax obligations handled for Ian McLeod’s Anika Therapeutics (ANIK) RSU vesting?

Tax obligations were satisfied by share withholding rather than a market sale. The company retained 639 shares of common stock at $14.96 per share, as disclosed, to cover taxes associated with the RSUs that vested on March 9, 2026.